AtriCure IncATRC

ATRC current price
$32.79-9.92%

Capital at risk.

1W
-4.15%
1M
-10.85%
3M
+16.24%
6M
+57.95%
1Y
-9.92%
MAX
+86.41%
About AtriCure Inc
Ticker
info
ATRC
Trading on
info
NASDAQ
ISIN
info
US04963C2098
Industry
info
Medical Instruments & Supplies
Sector
info
Healthcare
CEO
info
Michael H. Carrel
Headquarters
info
7555 Innovation Way, Mason, OH, United States, 45040
Employees
info
1,200
Website
info
atricure.com
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Metrics
BasicAdvanced
Market cap
info
$1.62B
P/E ratio
info
-
EPS
info
-$0.83
Dividend Yield
info
0.00%
Beta
info
1.41
Forward P/E ratio
info
0
EBIDTA
info
$-16.1M
Ex dividend date
info
-
Price & volume
Market cap
info
$1.62B
Average daily volume
info
0.4M
90-day return
info
16.24%
30-day return
info
-10.85%
7-day return
info
-4.15%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-1.18
Trailing P/E
info
0
Price to sales
info
3.63
Price to book
info
3.56
Earnings
EPS
info
-$0.83
EPS estimate (current quarter)
info
-$0.19
EPS estimate (next quarter)
info
-$0.15
EBITDA
info
$-16.1M
Revenues (TTM)
info
$448M
Revenues per share (TTM)
info
$9.56
Technicals
Beta
info
1.41
52-week High
info
$39.05
52-week Low
info
$18.94
50-day moving average
info
$32.47
200-day moving average
info
$27.11
Short ratio
info
2.59
Short %
info
3.58%
Management effectiveness
ROE (TTM)
info
8.39%
ROA (TTM)
info
3.51%
Profit margin
info
8.70%
Gross profit margin
info
$246M
Operating margin
info
6.39%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
17.90%
Share stats
Outstanding Shares
info
48.8M
Float
info
47.1M
Insiders %
info
3.18%
Institutions %
info
105.61%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 9 analysts.

Average price target

info
$45.11
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.21
-$0.23
8.70%
Q4 • 23Beat
-$0.28
-$0.23
21.74%
Q1 • 24Beat
-$0.17
-$0.17
-
Q2 • 24Beat
-$0.17
-$0.19
10.53%
Q3 • 24Beat
-
-
-
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$116M
$-8M
6.89%
Q2 • 24
$116M
$-7.9M
6.78%
Q3 • 24
0.31%
1.94%
1.63%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$597M
$135M
22.63%
Q2 • 24
$615M
$150M
24.40%
Q3 • 24
2.98%
10.99%
7.78%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$8.2M
$30.9M
$2M
$5.9M
Q2 • 24
$20M
$4.4M
$-0.3M
$16.4M
Q3 • 24
142.77%
85.78%
116.70%
179.99%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a AtriCure Inc share?
Collapse

AtriCure Inc shares are currently traded for $32.79 per share.

How many shares does AtriCure Inc have?
Collapse

AtriCure Inc currently has 48.8M shares.

Does AtriCure Inc pay dividends?
Collapse

No, AtriCure Inc doesn't pay dividends.

What is AtriCure Inc 52 week high?
Collapse

AtriCure Inc 52 week high is $39.05.

What is AtriCure Inc 52 week low?
Collapse

AtriCure Inc 52 week low is $18.94.

What is the 200-day moving average of AtriCure Inc?
Collapse

AtriCure Inc 200-day moving average is $27.11.

Who is AtriCure Inc CEO?
Collapse

The CEO of AtriCure Inc is Michael H. Carrel.

How many employees AtriCure Inc has?
Collapse

AtriCure Inc has 1,200 employees.

What is the market cap of AtriCure Inc?
Collapse

The market cap of AtriCure Inc is $1.62B.

What is the P/E of AtriCure Inc?
Collapse

The current P/E of AtriCure Inc is null.

What is the EPS of AtriCure Inc?
Collapse

The EPS of AtriCure Inc is -$0.83.

What is the PEG Ratio of AtriCure Inc?
Collapse

The PEG Ration of AtriCure Inc is -1.18.

What do analysts say about AtriCure Inc?
Collapse

According to the analysts AtriCure Inc is considered a buy.

AtriCure Inc news